Literature DB >> 34055210

PROTAC-Mediated Degradation of Bruton's Tyrosine Kinase as a Therapeutic Strategy for Cancer.

Robert B Kargbo1.   

Abstract

Entities:  

Year:  2021        PMID： 34055210      PMCID： PMC8155234          DOI： 10.1021/acsmedchemlett.1c00178

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN： 1948-5875            Impact factor:   4.345


× No keyword cloud information.
  5 in total

1.  Drug interactions with Bruton's tyrosine kinase inhibitors: clinical implications and management.

Authors:  Karen M Fancher; Jeremy J Pappacena
Journal:  Cancer Chemother Pharmacol       Date:  2020-09-17       Impact factor: 3.333

2.  Selective inhibition of thromboinflammation in COVID-19 by Btk inhibitors.

Authors:  Wolfgang Siess; Philipp Von Hundelshausen; Reinhard Lorenz
Journal:  Platelets       Date:  2020-09-06       Impact factor: 3.862

3.  BTK Inhibitors in Cancer Patients with COVID-19: "The Winner Will be the One Who Controls That Chaos" (Napoleon Bonaparte).

Authors:  Elise A Chong; Lindsey E Roeker; Mazyar Shadman; Matthew S Davids; Stephen J Schuster; Anthony R Mato
Journal:  Clin Cancer Res       Date:  2020-04-28       Impact factor: 12.531

Review 4.  Emerging bruton tyrosine kinase inhibitors for chronic lymphocytic leukaemia: one step ahead ibrutinib.

Authors:  Stefano Molica; Valentina Gianfelici; Luciano Levato
Journal:  Expert Opin Emerg Drugs       Date:  2020-02-06       Impact factor: 4.191

5.  A Fast and Clean BTK Inhibitor.

Authors:  Ronen Gabizon; Nir London
Journal:  J Med Chem       Date:  2020-05-13       Impact factor: 7.446
  5 in total
  1 in total

Review 1.  Discovery of E3 Ligase Ligands for Target Protein Degradation.

Authors:  Jaeseok Lee; Youngjun Lee; Young Mee Jung; Ju Hyun Park; Hyuk Sang Yoo; Jongmin Park
Journal:  Molecules       Date:  2022-10-02       Impact factor: 4.927
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.